Abstract
Many physiological and biochemical measurements can be performed noninvasively in humans with modern imaging techniques like magnetic resonance imaging (MRI), positron emission tomography (PET) or single-photon emission computed tomography (SPECT). This review focuses on the monitoring of drugreceptor interactions in patients and healthy volunteers with PET. Such studies depend on the availability of a suitable radioligand; they are already possible for classical and atypical neuroleptics, anxiolytics, antidepressants, anticholinergics, antihistamines, antiepileptics, beta-blockers and hypnotic drugs. In Phase I-II human studies, measurements of plasma pharmacokinetics can be combined with images of receptor occupancy and be quantitatively related to pharmacologic effects which are induced in the same subjects. Optimal dosing schedules can be defined and valuable information for the design of Phase III studies can be acquired. Moreover, the effect of interventions (e.g. change of dose, additional medication) can be predicted. Medical imaging techniques will play an increasing role in clinical pharmacology and allow well-informed go/no-go decisions in future drug development
Current Pharmaceutical Design
Title: Measuring Receptor Occupancy with PET
Volume: 6 Issue: 16
Author(s): Aren van Waarde
Affiliation:
Abstract: Many physiological and biochemical measurements can be performed noninvasively in humans with modern imaging techniques like magnetic resonance imaging (MRI), positron emission tomography (PET) or single-photon emission computed tomography (SPECT). This review focuses on the monitoring of drugreceptor interactions in patients and healthy volunteers with PET. Such studies depend on the availability of a suitable radioligand; they are already possible for classical and atypical neuroleptics, anxiolytics, antidepressants, anticholinergics, antihistamines, antiepileptics, beta-blockers and hypnotic drugs. In Phase I-II human studies, measurements of plasma pharmacokinetics can be combined with images of receptor occupancy and be quantitatively related to pharmacologic effects which are induced in the same subjects. Optimal dosing schedules can be defined and valuable information for the design of Phase III studies can be acquired. Moreover, the effect of interventions (e.g. change of dose, additional medication) can be predicted. Medical imaging techniques will play an increasing role in clinical pharmacology and allow well-informed go/no-go decisions in future drug development
Export Options
About this article
Cite this article as:
van Waarde Aren, Measuring Receptor Occupancy with PET, Current Pharmaceutical Design 2000; 6 (16) . https://dx.doi.org/10.2174/1381612003398951
DOI https://dx.doi.org/10.2174/1381612003398951 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets The Connections Among Autophagy, Inflammasome and Mitochondria
Current Drug Targets The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Therapeutic Drugs that Slow the Heart Rate of Early Rat Embryos. Is there a Risk for the Human?
Current Pharmaceutical Design Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Imaging of P-glycoprotein Function and Expression to Elucidate Mechanisms of Pharmacoresistance in Epilepsy
Current Topics in Medicinal Chemistry Preface: Vitamin D and QT Interval in Epilepsy: More than an Association?
Current Clinical Pharmacology Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review
Current Pharmaceutical Design tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Insulin Growth Factor-I Promotes Functional Recovery After a Focal Lesion in the Dentate Gyrus
CNS & Neurological Disorders - Drug Targets